CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
Anakinra (high dose) +3 moredrug
Likely dose
Anakinra (high dose) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01936844
NCT01936844Phase 3Completed
CompareCT.gov

Interleukin-1 Blockade in Acute Decompensated Heart Failure

Virginia Commonwealth University·interventional·Posted Sep 6, 2013·Updated May 5, 2016

In Brief

A Phase 3 clinical trial evaluating Anakinra (high dose), Anakinra (standard dose), and 1 other intervention for Heart Failure. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsAmerican Heart Association

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 6, 2013
Enrollment StartFeb 1, 2014
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.8 years ago

Interventions

Anakinra (high dose)drug

Anakinra 100 mg daily twice daily for days 1, 2, and 3

Anakinra (standard dose)drug

Anakinra 100 mg daily for days 4-14

Placebodrug

Placebo twice daily for days 1, 2, and 3

Placebodrug

Placebo daily for days 4-14